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Three decades after identiﬁcation of the Ras oncogene, no effective treatments for Ras mutant tumors are
available despite intensive drug discovery efforts. Here we critically review the attempts to inhibit Ras
function via direct binding of small molecules at the Ras surface with the aim to disrupt its interaction
with other proteins. Multiple binders at different binding sites have been discovered, and recent efforts
afforded crystal structures of Ras–binder complexes. Albeit with low afﬁnities, many of the binders were
shown to impart inhibitory activities, and inhibition of nucleotide exchange as a consequence of disrupt-
ing the Ras–SOS interaction has been the most commonly identiﬁed mode of action. We see two key chal-
lenges in the development of these early starting points: Enhancing binding afﬁnities and achieving
selectivity, both against other GTPases and for mutant Ras over the wildtype form. In light of the large
unmet medical need, we encourage the continued search for functionally active Ras binders, and we
believe that integrated use of biophysical and biochemical tools will provide the highest chances for suc-
cess. Given the failures experienced in the past and the signiﬁcant hurdles ahead, we propose that this
challenge be tackled through alliances between industry and academia.
Published by Elsevier Ltd. Open access under CC BY-NC-ND license.The small G-proteins K-Ras, H-Ras, and N-Ras function as
GDP–GTP regulated binary switches in many signal transduction
pathways that govern cell growth and differentiation. Alternation
between the GDP-bound ‘off’ state and the GTP-bound ‘on’ state
is controlled by the guanine nucleotide exchange factors (GEFs)
SOS1 and SOS2, which catalyze the exchange of GDP for GTP, and
by GTPase-activating proteins (GAPs), which terminate the ‘on’
state by catalyzing the hydrolysis of GTP to GDP (Fig. 1). In the ac-
tive state, Ras signals to a spectrum of functionally diverse down-
stream effector proteins, such as Raf, PI3K, and Ral-GDS. The
catalytic domain of Ras is highly homologous between the three
Ras isoforms K-Ras , H-Ras, and N-Ras, however major differences
are found in the C-terminal hypervariable region (HVR) of these
proteins. The latter part of these proteins is involved in membrane, farnesyltransferase; FTmap,
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 CC BY-NC-ND license.association, which is a critical requirement for downstream
signaling.
Gain of function mutations in Ras proteins are frequently found
in human cancers and represent poor prognosis markers for pa-
tients.1 These mutations occur mostly in codons 12, 13, and 61
and render these forms resistant to GAP-catalyzed hydrolysis and
chronically active. Mutations of the K-Ras isoform constitute some
of the most common aberrations among all human cancers and oc-
cur in three of the top four neoplasms that cause cancer deaths in
the USA: lung, colon, and pancreatic cancer.1 Studies in animal
models provided strong evidence for inhibiting Ras as a therapeutic
strategy2–4 and, consequently, intensive drug discovery efforts
have been directed toward targeting Ras. Yet, in 2012, three dec-
ades after the discovery of the Ras genes, this goal has not led to
any effective solutions. Drug discovery efforts have mainly focused
on inhibiting posttranslational modiﬁcation steps, targeting the
Ras protein directly, or utilizing indirect strategies, namely inhibi-
tion of downstream effectors.5 Phenotypic approaches, such as tar-
geting synthetic lethality, have recently been explored as an
alternative strategy (Table 1). The focus of this review will be a dis-
cussion of efforts aimed at targeting Ras directly, and a critical
assessment of the status, challenges, and therapeutic potential of
this concept will be provided.
In the last 15 years, major efforts have been directed toward
developing inhibitors of Ras effectors. Driven by experimental val-
idation for their critical role in Ras-driven oncogenesis and by the
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Figure 1. Schematic depiction of the major steps of the RTK-SOS-mediated-signaling. Binding of growth factor to RTK leads to its phosphorylation triggering recruitment of
SOS to the plasma membrane. Membrane-localized SOS activates Ras by facilitating exchange of GDP for GTP. Activated Ras stimulates numerous signaling pathways
controlling cellular processes such as proliferation and differentiation. GTP in activated Ras is hydrolyzed with the assistance of GTPase activating proteins (GAPs) to form
Ras-GDP.
Table 1
Disrupting Ras signaling —drug discovery strategies
Direct, targeted  Disrupt Ras processing/localization
 Decrease Ras-GTP:Ras-GDP balance
 Block Ras-effector interaction
Indirect, targeted  Inhibit downstream effectors
Phenotypic  Identify synthetically lethal partner targets of
mutant K-Ras via RNAi screens
 Functional screens (small molecule libraries)
W. Wang et al. / Bioorg. Med. Chem. Lett. 22 (2012) 5766–5776 5767ﬁnding of mutant B-Raf, PTEN deﬁciency, and mutant PI3K in hu-
man cancers, the Raf-MEK-ERK and PI3K-AKT-mTOR signaling
pathways have been the most extensively targeted. Inhibitors of
Raf kinase have shown clinical beneﬁt in the treatment of B-Raf
mutant metastatic melanoma, but failed to show beneﬁt in Ras
mutant tumors.5 It remains unclear to what extent Ras depends
on Raf kinase for transforming activity, even though Raf proteins
bind directly to Ras and are important Ras effectors in normal cells.
Furthermore, Raf kinase inhibitors can lead to paradoxical activa-
tion, rather than inhibition, of the MAPK pathway in Ras mutant
tumor cells, a clinically relevant ﬁnding.6,7 In addition, resistance
has been observed upon prolonged treatment with B-Raf inhibi-
tors, and multiple mechanisms have been identiﬁed, including
activation through N-Ras mutations.8 Similarly, MEK inhibitors
block the Ras-MAPK pathway, but often activate the phosphoinosi-
tide 3-kinase (PI3K) pathway, and have shown little clinical beneﬁt
in Ras mutant tumors as single agents. This activation is mediated
by receptor tyrosine kinases through relief of a negative feedback
loop from ERK to SOS.9,10
The PI3K pathway is another well-studied signaling cascade
downstream of Ras. Although PI3K signaling plays an important
role in Ras-mediated tumorigenesis, current data suggest that
Ras mutant tumors are insensitive to single-agent PI3K inhibitors.5
It becomes increasingly clear that inhibiting any single Ras effector
pathway is unlikely to provide therapeutic efﬁcacy in Ras mutantFigure 2. Schematic presentation of the cascade of post-translational modiﬁcation react
step, Ras is farnesylated by farnesyltransferase (FTase) before undergoing proteoly
carboxymethylation by isoprenylcysteine carboxymethyltransferase (ICMT). H-, N-, and K
the membrane. K-Ras 4B can anchor in the membrane without appendage of a palmitoyl
localization step of farnesylated Ras to Ras docking proteins (galectins) located at the mtumors. Drug combinations that target multiple points within the
Ras signaling network are likely to be necessary to achieve sub-
stantial clinical beneﬁt, but the toxicity of combination therapy is
a major concern.
Ras is recruited to the cytoplasmic membrane where it exerts
signaling activity (Fig. 2). A cascade of post-translational modiﬁca-
tions on Ras, including linkage of a farnesyl group, mediates Ras
membrane localization. An early research focus was inhibiting
the farnesyl transferase step with small molecules, and extensive
efforts were directed both in industry and in academia toward
identifying suitable small-molecule drugs (Scheme 1). Two com-
pounds, Tipifarnib (1) and Lonafarnib (2),1 proceeded to Phase II/
III clinical trials, but lacked efﬁcacy, as the most frequently mu-
tated Ras isoform (K-Ras) can be modiﬁed by a compensatory
mechanism of geranylgeranylation.11 Combination of farnesyl
transferase and geranylgeranyl transferase inhibitors is associated
with intolerable toxicity. Other efforts focused on the ‘post-
prenylation’ processing enzymes RCE1 and ICMT,12 but these
enzymes, like farnesyl transferases, have many substrates besides
Ras and are expected to provide low safety margins. The currently
best-studied example of a selective ICMT inhibitor is the investiga-
tional compound cysmethynil (3), but neither this compound nor
other ICMT inhibitors have proceeded into clinical trials. Farnesyl-
cysteine mimetics, which compete with Ras for binding to the
membrane associated escort proteins (galectins), have also been
explored, and an investigational compound, salirasib (4) proceeded
to Phase I/II clinical trials for hematopoietic disease as well as pan-
creatic and lung cancers.13 There is evidence that salirasib pos-
sesses multiple modes of action, and it is unclear if the
therapeutic effects are predominantly driven by competitive galec-
tin binding. Another competitive galectin binder, TLN-4601 (5),
failed in clinical trials.1
The crystal structures of Ras proteins display a typical GTPase
fold that comprises a six-stranded b-sheet in the center and ﬁve
a-helices ﬂanking on the sides (Fig. 3a). The N-terminal domain
(residues 1–86) contains the GTP binding site, the switch regionsions of Ras that culminate in the binding of Ras to the inner membrane. In the ﬁrst
tic removal of the AAX tripeptide by Ras converting enzyme 1 (RCE1) and
-Ras 4A require an additional palmitoylation step (not shown) to be able to insert to
moiety. Inhibitors for each of these steps have been identiﬁed, including for the ﬁnal
embrane.
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Scheme 1. Inhibitors of Ras post-translational modiﬁcation and localization.
5768 W. Wang et al. / Bioorg. Med. Chem. Lett. 22 (2012) 5766–5776(switch 1 and 2), and residues contacting GEF, GAP, and effector
proteins. The presence of GTP or GDP alters the conformation in
the switch regions: In the active GTP bound state, switch 1 and 2
both interact with the c-phosphate moiety of GTP under consider-
able conformational strain, and this strain is released upon conver-
sion to the GDP bound state. GDP or GTP bound state represent
conformational states with either high or low afﬁnity to effectors;
only in the GTP bound state Ras is able to signal downstream. The
switch region of the protein sequence is conserved among H-, K-,
and N-Ras. In contrast, the C-terminal domain (residues 87–172)
of Ras contains a more variable sequence. This part of the protein
is involved in interactions with the cytoplasmic membrane, but
otherwise functionally less understood. The 17 C-terminal residues
comprise a hyper-variable region (HVR). It harbors one or two pre-
nylation sites that facilitate membrane localization. Uniquely to K-
Ras4B, a polylysine sequence is present in the HVR and promotes
membrane localization, abrogating the requirement of an addi-
tional palmitoylation step prior to anchoring to the membrane
(Fig. 3a). The Ras structure has a relatively ﬂat surface. Outside
the nucleotide-binding grove there are no cavities obviously suit-
able for small molecule ligand binding. Although generally ac-
cepted, this view may neglect the conformational dynamics of
the Ras protein and the transient opening of surface pockets not
fully apparent in ‘ligand-free’ crystal structures.14 Furthermore,
allosteric interactions between the effector-binding domain (N-
terminal) and the membrane-binding domain (C-terminal) appear
to play a critical role in regulating Ras activity.14–16 Ligands binding
at the domain interface can potentially interfere with the Ras func-
tion in an allosteric manner.
A major focus of in silico analyses has been to identify potential
binding sites on Ras and subsequently predict small-molecule li-
gands suitable for binding at those sites. Interestingly, despite sub-
stantial differences in the methods used, there is good agreement
in the prediction of certain ligand binding sites. The following
paragraphs provide representative examples.
Te Heesen et al. applied a pragmatic approach by evaluating
surface pockets, identiﬁed by a generic surface calculation, and
taking into account the drug-likeness of predicted small molecule
binders.17 This reduced the number of pockets to a more ‘drugga-
ble’ subset, including site 3 (extended site exists in the region be-
tween switch II and helix 3), site 4 (regions between switch II,
phosphate-binding loop (P-loop), and the back-side of loop 8),
and a relatively small but observable site 5 (adjacent to loop 7)
in Fig. 3b. A comparison of the active and inactive form of Rasshowed clear differences in the location of some predicted binding
sites, raising the possibility of speciﬁcally targeting activated Ras.
Protein–ligand interactions usually involve energetic ‘hotspots’
which are certain regions of a protein surface that contribute the
majority of binding free energy, disproportional to its surface
area.18 Targeting the ‘hotspots’ is particularly important for inhib-
itors of protein–protein interactions (PPI), and fragment screening
is thought to be an effective method of searching for hotspots.19
Mattos et al. pioneered an X-ray crystallographic technique known
as multiple solvent crystal structures (MSCS) to probe the protein
surface with small solvent molecules.20 To mimic such a process
purely computationally, Brenke et al. developed a fast Fourier
transform correlation mapping algorithm (FTmap), which rapidly
samples billions of probe positions on dense translational and rota-
tional grids.21 Using MSCS and FTmapp in parallel, Buhrman et al.
mapped out the Ras surface, and derived complementary sets of li-
gand binding sites (Fig. 3b, Table 2).15
The structurally most ﬂexible regions, ‘switch 1’ and ‘switch 2’,
give rise to the transient formation of surface pockets. Some of
these transient pockets are partially revealed in crystal structures
while some others can be derived from molecular dynamics simu-
lations. Using multiple mapping methods including FTmap, Grant
and co-workers mapped the entire ensemble of Ras conformations
derived both experimentally and computationally.22 Analysis of
the union of consensus sites identiﬁed four main regions of poten-
tial ligand-binding. A virtual screen using compounds from public
libraries against these sites indicated the highest propensity of li-
gand binding at a site located between loop 7, loop 9, and helix 5
(site 5). They followed up with functional cellular assays and
showed that three of the hit compounds imparted a reduction in
Ras-GTP levels and decreased downstream signaling. However,
no experimental evidence of direct binding to Ras was provided,
and the exact inhibitory mechanism remains unclear. Cellular
activities of these compounds were observed at concentrations
above 10 lM, and the possibility of off-target effects cannot be ru-
led out.
The quality and accuracy of the computational predictions are
variable given the limitations of each method. However, consensus
among orthogonal methods tends to be more meaningful. Fig. 3b
depicts the level of consensus of all predicted ligand-binding sites.
Among the high consensus regions, sites 1 through 4 are clustered
around the switch regions, whereas site 5 is located at the interface
between the catalytic (residues 1–86) and allosteric (residues 87–
171) domains. As shown later, these sites are indeed associated
Figure 3. Ras structure and ligand binding sites. (a) The crystal structure of full length K-Ras4B28 shown as a ribbon diagram. Secondary structure elements are labeled. The
switch 1 region is colored in green and the switch 2 region in orange. The stick model shows a GTP molecule bound to the nucleotide-binding site. The green sphere is a Mg2+
ion bound to GTP. The C-terminal segment is composed of amino acid residues displayed in letters and contains a poly-lysine stretch presumably interacting with the
membrane. The C-terminus is disordered in the crystal structure and therefore depicted as a dotted line. (b) The ligand binding sites identiﬁed experimentally or
computationally are mapped onto the full length K-Ras crystal structure (shown in two views, front and back, for convenience). The areas of the K-Ras surface involved in
ligand binding are color-coded. The sites are classiﬁed based on the level of consensus among different predictions; green: low, yellow: medium, red: high. Ligands that were
found to bind at individual sites are listed in the text boxes. Solvent-like probes from MSCS are shown in black text. Abbreviations: ETF, 2,2,2-triﬂuoroethanol; GOL, glycerol;
RSF, R,S,R-bisfuranol; RSG, S,R,S-bisfuranol; HEZ, 1,6-hexanediol; YEG, cyclopentanol; HEX, hexane; DMF, dimethylformamide; ACT, acetate; BDZN, benzamidine; BZIM,
benzimidazole; (c) The crystallographically determined ligands are shown as sticks. The representative contact residues for Raf and SOS1 are depicted as colored patches. Left,
blue: Raf-RBD binding site; right, orange: SOS1 binding site. Site 2 is in the vicinity of a region that interacts with both RBD and SOS1.
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Table 2
Ras binders and observed functional effects
Binding site Compound PDB codes of co-crystal structures Mechanism
Site 1 (Switch 1) regions 16 (HBS3 peptide)30 — Block SOS mediated nucleotide exchange30
Site 2 (H2 and S3) 927, 10 (DCAI)28; 11–
1529*
4DSO,28 4DST,28 4DSU,28 4EPV,29 4EPW,29
4EPT,29 4EPX,29 4EPR29
10, 15b, 15c: Block SOS mediated nucleotide exchange28,29
Site 3 (between switch 2 and
H3)
6 (SCH-54292)23; 7;
826
— 6: Block nucleotide exchange23
Site 4 (on top of a-
phosphate)
17 (Zn2+-cyclen)32 — Stabilize a conformational state of Ras with a low afﬁnity
to effector proteins32
Site 5 (Loop7) 17 (Zn2+-cyclen)32
(second site)
3L8Y32 —
Proximity to switch regions
(undeﬁned)
19 (Sulindac
sulﬁde)33,34
— Block formation of Ras–Raf complex33,34
Unknown 20 (MCP110)38,39 — Block formation of Ras–Raf complex38,39
* NSC23766 (21) binds to the equivalent site on Rac1.45
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Scheme 2. Reported Ras binders.
5770 W. Wang et al. / Bioorg. Med. Chem. Lett. 22 (2012) 5766–5776with a higher frequency of experimentally observed ligand
binding.
Several groups recently succeeded with the experimental iden-
tiﬁcation of small-molecule binders to Ras. Encouragingly, the
identiﬁed binding sites agree with the sites of highest predictionconsensus, and many of the binding sites appear to be functionally
relevant (Table 2, Fig. 3b). An overview of the known Ras surface
binders and their mechanistic effects is shown in Table 2 and
Scheme 2. The binders with more accurately characterized
binding sites were found to have a functional effect on nucleotide
W. Wang et al. / Bioorg. Med. Chem. Lett. 22 (2012) 5766–5776 5771exchange. Curiously, the compounds with a proven effect on
disrupting effector protein (Raf) interaction, MCP110 and sulindac
derivatives, lack such stringent biophysical characterization.
SCH-54292 and derivatives: SCH-54292 (6) was discovered in a
program to identify compounds that bind to Ras at a site different
from the active site and inhibit exchange from Ras-GDP to
Ras-GTP.23 The compound was conﬁrmed to bind to Ras24 and
exhibited inhibitory activities against GEF-independent intrinsic
nucleotide exchange25 with IC50’s ranging from 0.5 to 0.7 lM. It
is unclear whether it also inhibits GEF-catalyzed nucleotide
exchange. A breakthrough in this study is the identiﬁcation of
the compound-binding site. Guided by NMR mapping, 6 was
docked onto the crystal structure of Ras. The docking model postu-
lates that 6 binds in a cleft adjacent to the switch 2 region (site 3 in
Fig. 3b) in a binding mode consistent with 6 being selective for the
Ras-GDP state. The phenylhydroxylamine moiety of 6 is situated
near the Mg2+ ion and potentially serves as a chelator, thereby
enhancing its binding afﬁnity. A close analogue of 6, SCH-53870
(7), displayed moderate inhibitory activity (EC50 10–20 lM) in a
cellular assay while other compounds were inactive in this assay,
presumably due to poor cell permeability.23
The compound binding and activity appear to be highly depen-
dent on the metal-chelating phenylhydroxylamine moiety, an
undesirable functional group. The experience from other medicinal
chemistry programs suggests that replacing metal-chelating
groups or overcoming the dependency on them altogether can be
highly challenging. Such optimization efforts would greatly beneﬁt
from high-resolution crystal structures, which to date have not
been reported with compounds from this class.
Guided by molecular modeling, Peri et al. later reported modiﬁ-
cations to 6with a novel bicyclic scaffold derived from D-arabinose,
while maintaining the benzyl and the phenylhydroxylamine moie-
ties essential for Ras binding. Analogues from this series showed
improved activities compared to 6. For example, compound 8
inhibits GDP dissociation more strongly, and the amide linker im-
parts higher cell permeability.26
Efforts to increase water solubility of 6 led to the identiﬁcation
of compound 9 containing more substantial structural modiﬁca-
tions, an O-benzyl-N-(3,4-dihydroxybenzyl) hydroxylamine moi-
ety that is N-glycosylated with D-glucose.27 The hydroxylamine
moiety is benzylated in compound 9 and no longer available for
coordination with the Mg2+ ion. 9 only weakly inhibits GEF-
catalyzed nucleotide exchange (IC50 = 100 lM). NMR mapping
suggests that 9 interacts with site 2, while the molecular dynamics
and docking results favor the cleft at site 3. Removal of the phen-
ylhydoxyamine moiety is a signiﬁcant structural change from theFigure 4. Ras ligand binding revealed in co-crystal structures. The binding site is locat
published by Maurer et al. Magenta: 10; cyan: benzimidazole; yellow: benzamidine. (b
yellow: 15b.original SCH compounds. It is possible that 9 interacts with Ras
in a different way and at a different site, and further characteriza-
tion of the molecular interactions will be required to gain more de-
tailed insights.
DCAI (4,6-dichloro-2-methyl-3-aminoethyl-indole): DCAI (10)
represents a signiﬁcant advancement in the pursuit of Ras inhibi-
tors. 10was discovered through an NMR-based fragment screening
effort.28 Maurer et al. identiﬁed a group of small molecules that all
bind to a common site on Ras. Unlike previously reported com-
pounds with scarce structural information, binding of 10 and other
compounds to Ras has been characterized by X-ray crystallography
(Fig. 4a). The high-resolution co-crystal structures delineated a un-
ique ligand-binding pocket on the Ras surface overlapping with
site 2 (Fig. 3), which can be expanded by compound binding. Struc-
ture analysis predicted that compound binding would interfere
with the Ras/SOS interactions. Indeed, selected compounds inhib-
ited SOS-mediated nucleotide exchange and prevented Ras activa-
tion by blocking the formation of intermediates of the exchange
reaction.28 While Ras binders with effects on nucleotide exchange
had previously been reported, this study provides for the ﬁrst time
high resolution structural information on functionally active li-
gands bound to the full-length K-Ras. The combination of co-
crystal structures and detailed biochemical studies appeared to
be particularly effective in elucidating the inhibitory mechanism
for fragments with weak binding afﬁnity.
Indole analogues: Sun et al. conducted an independent NMR
fragment screening study and discovered compounds that bind to
site 2 (Scheme 2, compounds 11–14) with an afﬁnity of 1.3–
2 mM.29 Expanded analogueswere shown to extend to site 1 afford-
ing signiﬁcantly improved binding afﬁnities compared to unsubsti-
tuted counterparts. For example, the indole analogues 15b and 15c
bind to K-RasG12D-GDP with a KD of 190 and 340 lM, respectively,
compared to a KD of 1300 lM of the unsubstituted analogue
15a. This represents the ﬁrst reported example of successful afﬁnity
improvement of Ras binding molecules using structure-guided de-
sign. Similar to 10 described above, these compounds block the
interaction between Ras and SOS, thereby inhibiting SOS-mediated
nucleotide exchange (Table 2 and Fig. 4b).29 Differently from 15b
and c, compound 10 does not reach into site 1 indicating that this
is not a requirement for disrupting the Ras–SOS interaction. How-
ever, expanding into the direction of site 1imparts greater overlap
with the Raf binding epitope improving the chance to orthosterical-
ly inhibit the interaction with Raf (Fig. 3c). No data were reported
for 15 to support this hypothesis; nevertheless, this series repre-
sents an interesting starting point for further medicinal chemistry
efforts aimed at enhancing binding afﬁnity and functional activity.ed between a-helix 2 and b-strand 3, adjacent to switch 1 and 2. (a) Compounds
) Compounds published by Sun et al. Cyan: 11; magenta: 12; pink: 13; white: 14;
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5772 W. Wang et al. / Bioorg. Med. Chem. Lett. 22 (2012) 5766–5776HBS3 peptide: The synthetic HBS3 peptide (16) was designed as
an orthosteric inhibitor that disrupts the SOS1–Ras protein interac-
tion and inhibits SOS1-mediated nucleotide exchange. The aH he-
lix of SOS1 is known to be the key structural element interacting
with Ras. 16, a peptidyl mimetic of SOS1 aH, was shown to bind
to nucleotide-free Ras with a KD of 28 lM and to GDP-bound
Ras with a KD of 158 lM. An NMR mapping study indicated that
16, similar to 15b and c, bind between site 1 and site 2 and spans
the nucleotide-binding pocket, supporting the prediction that 16
can act as a direct mimic of the aH helix in SOS1.30 16 inhibited
SOS1-mediated nucleotide exchange with an IC50 of 25 lM. 16
may prove useful as a tool to discover other compounds targeting
this site on Ras.
Cyclen derivatives: Ras function is tightly correlated with its
conformation. The effectors bind to the active conformation with
signiﬁcantly higher afﬁnity than to the inactive conformations.
Spoerner and co-workers used 31P NMR as a sensitive means of
monitoring the Ras conformations in solution and showed that
multiple Ras conformations co-exist in equilibrium.31 The authors
discovered that binding to Ras by Zn2+-cyclen (17) shifted the Ras
conformational equilibrium towards an inactive conformation.
Rosnizeck et al. later conﬁrmed that both 17 and Cu2+-cyclen
(18) stabilize a conformational state of Ras-GTP with a low afﬁnity
to effector proteins.32 NMR chemical shifts indicated that there are
two binding sites for 17 (site 4 and site 5 in Fig. 3b) on Ras that can
be saturated at 2 mM and 6 mM compound concentrations, respec-
tively. Binding of 17 at the distal site 5 was demonstrated by crys-
tallography. While metal-cyclens are not drug-like, these studies
revealed sites on Ras that are distinct from the ones characterized
by other approaches. In an independent study15, calcium acetate
was found to bind at the site 5, but no functional studies were per-
formed. Further investigation will be required to assess the general
utility of this binding site for allosteric modulation.
Sulindac derivatives: Sulindac, a non-steroidal anti-inﬂammatory
drug, has been used in cancer preventative therapy. Under physio-
logical conditions sulindac is metabolized into sulindac sulﬁde
(19). Herrmann et al. reported that 19 strongly inhibits Ras induced
malignant transformation and Ras-dependent activation of Raf.33
Using biophysical methods, they demonstrated that 19 binds
reversibly to Ras, and the 15N HSQC spectra suggested a binding
site in proximity to the switch regions of Ras.34 Biochemical assays
revealed impairment of the interaction of Ras with the partner pro-
teins SOS, Raf, and other effectors in the potency range of 100–
200 lM.33–35 The primary liabilities of the sulindac derivatives
are their poor potency and promiscuous pharmacological ef-
fects,36,37 confounding the interpretation of cellular data. Besidesthe NMR-based binding site mapping, which conﬁrmed direct
binding to Ras and provided insights into the mechanism of action,
high-resolution crystal structures, currently unavailable, would be
highly desirable for rationally designing inhibitors with improved
potency, selectivity, and drug-likeness.
MCP compounds: Using a yeast two-hybrid system, Kato-
Stankiewicz et al. discovered a series of compounds that inhibit
the formation of the Ras–Raf complex.38 In a recent study, this
effect was more precisely deﬁned as an interference of the interac-
tion between Ras and the Ras binding domain of Raf (Raf-RBD).39 A
selected compound, MCP110 (20), at 3–30 lM concentration
blocked the physical interaction between Ras and Raf-RBD and
functionally impaired the Ras-Raf-MEK-ERK pathway both in vivo
and in cell-based systems,38,40 but it is not known whether this
compound or analogs directly bind to Ras or Raf. A subsequent
chemical analoguing study revealed no conclusive SAR trends,
and it is unclear if the observed functional activities originate from
a common mechanism.41
The Ras superfamily comprises over 150 members42 that func-
tion as molecular switches in diverse cellular processes. Their func-
tional diversity is augmented by differential sub-cellular
localization and tissue distribution. Identifying means of inhibition
is a major challenge not limited to Ras, but small G-proteins in gen-
eral. To date, only a few small molecule inhibitors were found to
directly bind to this family of proteins. In this section we will re-
view compounds reported in the literature since they can provide
valuable lessons applicable to the search of inhibitors for Ras and
G-proteins in general.
Rac1 belongs to the Rho subfamily of small G-proteins. Exces-
sive Rac activity has been associated with cancer,43 cardiovascular
diseases,43 Alzheimer’s disease,44 and other conditions. The discov-
ery of Rac1 speciﬁc small-molecule inhibitors is therefore of signif-
icant interest.
Two series of Rac1 inhibitors have been reported in the
literature (Scheme 3). The ﬁrst was discovered through a struc-
ture-based virtual screen.45,46 A representative molecule from this
series, NSC23766 (21) blocked the physical interaction between
Rac1 and Trio, the cognate GEF for Rac1, in a GST pull-down assay.
21 appeared to inhibit Rac1 activation biochemically and in cellu-
lar assays.44,45 The binding site of 21 is located in the shallow pock-
et between H2 and S3,47 which is the corresponding binding site of
10–14 (site 2) in Ras.28 It is intriguing that 21 not only binds to an
equivalent site but also causes similar functional effects, suggest-
ing that site 2 is generally sensitive to ligand modulation. There
are signiﬁcant amino acid sequence differences between Ras and
Rac1 at this site;48interestingly, sequence variability at this site is
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be exploited for identifying selective GTPase inhibitors.
The second series of inhibitors was originally discovered in a
functional screen49 and a representative compound, EHT1864
(22), later found to disrupt Rac1 interaction with its effector
PAK1.44 This series appeared to selectively affect Rac1, as in a
GST pull-down assay at 25 lM concentration 22 blocked Rac1-
GTP binding to PAK1 but had no effect on RhoA. The blockage of
this protein–protein interaction seemed to have a functional con-
sequence as 22 was found to speciﬁcally inhibit Rac1 signaling.
Studies have implicated Rac1 in the modulation of APP processing
and Ab production,48 and 22 was shown to attenuate b-amyloid
peptide production in vitro and in vivo.44 Although 22 was shown
to directly interfere with Rac1 PAK1 binding, more detailed knowl-
edge about the interaction between compound and protein will be
required to elucidate its inhibition mechanism and to optimize this
series of compounds.
An unconventional mode of inhibiting small G-proteins is ob-
served for Brefeldin A (23). 23 is a natural product that inhibits
membrane transformation and cellular trafﬁcking regulated by
Arf1.50 Arf1 is a small G-protein with ARNO as its cognate GEF.
Through an uncompetitive mechanism, 23 traps Arf1-GDP and
ARNO into an abortive complex that cannot proceed to the subse-
quent nucleotide dissociation step51,52 (Fig. 5). At a concentration
of 25 lM, 23 does not bind to either Arf1-GDP or ARNO alone, pro-
viding a paradigm example of an interfacial inhibitor. Using an in
silico screen targeting a ﬂexible pocket near the Arf1/ARNO inter-
face, another interfacial binder, LM11 (24), was discovered. 24 dis-
plays a very similar binding mode to 23, but traps the Arf1–ARNO
complex at a conformationally distinct later stage of the nucleotide
exchange reaction.53
We propose ﬁve theoretical mechanisms to inhibit Ras via bind-
ing to its surface:
(1) by GTP-competitive binding
(2) by restoring the GTPase activity compromised in mutant Ras
(3) by inhibiting the Ras nucleotide exchange factors, such as
SOS
(4) by blocking the Ras-effector interactionsFigure 5. Brefeldin A (23) sequesters the ARNO/Arf1 complex and inhibits
nucleotide exchange.(5) by trapping Ras in an inactive conformation incompatible
with effector binding and signaling
Ras and other small G-proteins possess a natural nucleotide-
binding pocket that accommodates GTP and GDP. Presence of the
c-phosphate in GTP-bound Ras forms the basis for maintaining
the protein in a state capable of high-afﬁnity binding to effector
proteins. The idea of developing GTP mimics, similar to ATP mimics
in the ﬁeld of kinase inhibitors, had been initially considered but
rapidly discarded. Guanine nucleotides bind with picomolar afﬁn-
ity (KD = 1012 M) to Ras and occur in sub-millimolar cytosolic GTP
concentrations, making it extremely challenging to develop inhib-
itors capable of competing off nucleotides. Conversely, the afﬁnity
of ATP for kinases is typically >1000-fold lower. Furthermore, ATP
in kinases is used for rapid catalytic phosphoryl transfer, while the
nucleotides in Ras stabilize inactive or active states, and it is ques-
tionable if the concept of GTP competitive inhibition could be lev-
eraged in the same way as ATP-competitive inhibition for kinases.
It is therefore unlikely that the concept of GTP-competitive inhibi-
tion is applicable for Ras.
A hallmark feature of oncongenic Ras mutants is their insensi-
tivity to the action of GTPase activating proteins (GAPs). GAPs
are critical for stimulating the intrinsically low GTPase activity of
Ras. One of the earliest efforts made to inhibit Ras was therefore
to identify small molecules that restored GAP sensitivity to mutant
Ras, an approach that will yield inhibitors speciﬁc to mutant
Ras.54,55 Ideally, such compounds would mimic the effects of GAP
and insert an arginine-like residue that would facilitate GTP hydro-
lysis in the mutant protein. Unfortunately, small molecule screen-
ing campaigns failed to ﬁnd compounds that would bind and
interact at the site of action. A closer look at the structural features
of mutant Ras provides some clues. The most common mutation in
K-Ras is a glycine to aspartate mutation at position 12 in the
GTPase catalytic domain. The lack of a side chain in glycine gives
sufﬁcient room for GAP to insert an arginine residue into the cata-
lytic site, stabilizing the negative charge of the phosphate interme-
diate formed during the reaction. Substitution of glycine for any
amino acid with a bulkier side chain occludes the access by this
arginine residue, explaining the insensitivity of this mutant to
hydrolysis (Fig. 6). This occlusion poses an obstacle not only to
GAP but also to any small molecule potentially mimicking GAP.Figure 6. The oncogenic mutation G12D blocks GAP activity. The crystal structure
of H-Ras and GAP (PDB code: 1WQ154) suggests that a bulky residue replacement at
the G12 position will clash with the ﬁnger loop and hinder GAP from catalyzing the
GTPase reaction. GAP is colored in red. H-Ras is colored in white. The structure
captures a GTP hydrolysis transition state using a corresponding arrangement of
GDP and AlF3 (colored in yellow).
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likely not accessible to any molecule aiming to stabilize the GTPase
transition state. The second most frequent Ras mutation is substi-
tution of Gln-61. The Gln-61 side chain constitutes the heart of the
catalytic center, and restoration of the catalytic competence of Ras
through a small molecule binder at this area is not conceivable.
Many of the Ras binders identiﬁed to date bind near or overlap
with the surface involved in the association with the nucleotide ex-
change factor, and most of these compounds were shown to inhibit
nucleotide exchange. Some of these compounds were identiﬁed
from fragment screens, which provide an excellent experimental
approach to determine the druggability of challenging therapeutic
targets.19 An impressive testimony to the power of this approach
was the identiﬁcation of inhibitors of Bcl2, a target that previously
had been considered undruggable.56 Even with better tools in
hand, increasing the binding afﬁnity of the identiﬁed Ras binders
will be extremely challenging and will require well-conceived
strategies beyond simple expansion of ﬁrst generation binders.
Inhibition of protein–protein interactions is thermodynamically
challenging, and stabilizing an abortive complex rather than break-
ing of a PPI might represent a more viable strategy.57,58 In fact, this
has been demonstrated by the small molecule Brefeldin A (23) in
the Arf-Arno system, as discussed above. As 23 shows no afﬁnity
to either protein alone, it will clearly be necessary to devise screens
that are speciﬁcally designed to identify interfacial binders.
Apart from the challenge of druggability, it is critical to assess
the therapeutic potential of inhibiting the nucleotide exchange
reaction. Mutant Ras is locked in the active GTP-bound state and
is expected to be less dependent on nucleotide exchange factors
for its activation. Hence, blocking the interaction with nucleotide
exchange factors may have a greater effect on the activation of
wild-type Ras than the mutant Ras, an undesirable therapeutic out-
come. However, there is accumulating evidence that mutant and
wild-type Ras isoforms signal to different downstream pathways
and are both required for oncogenic transformation. Furthermore,
the activation of wild-type Ras isoforms may be potentiated by
mutant Ras. This potentiation mechanistically occurs through allo-
steric activation of SOS by abundant mutant Ras-GTP.59 The impli-
cations and generality of this positive feedback mechanism are not
fully understood, but it might suggest the utility of a SOS inhibitor
even in a Ras mutant context. Nevertheless, the question of a suf-
ﬁcient therapeutic window with inhibition of SOS remains. While
SOS inhibitors could be efﬁcacious in wild-type Ras tumors, partic-
ularly in combination with Raf pathway inhibitors,9,10 the impor-
tance of mutant Ras and resilience to available treatments are the
primary reasons for targeting this class of enzymes.
Given that Ras exerts all its biological functions through binding
to downstream effectors, inhibiting Ras–effector complexes is
likely to provide the best efﬁcacy in Ras mutant tumors. Ras signals
to over a dozen different downstream effector pathways, and it re-
mains to be determined which of these effector pathways need to
be inhibited to elicit therapeutic effects. The effector-binding sites
on Ras partly overlap the SOS binding site (Fig. 3c), and targeting
former sites with small molecules is believed to face similar, if
not greater, challenges as discussed for the disruption of the Ras–
SOS interaction. The effector interaction surfaces consist of helix
1, switch 1, and the edge of the b-sheet. Apart from the ﬂat surface,
the challenge of identifying small molecule ligands binding at this
site also arises from the dynamic nature of the switch 1 loop. Nev-
ertheless, two small molecules, sulindac sulﬁde (19)33,34 and
MCP110 (20)38,39 were found to disrupt the interaction between
Ras and Raf. While there is some knowledge of the binding site
of sulindac sulﬁde (19) (see above), there is no information on
the binding site of MCP110 (20). Interestingly, this parallels the sit-
uation for EHT1864 (22) in the related GTPase-effector system
Rac1-PAK1. More detailed biophysical characterization of thesecompounds would be valuable. The concept of interfacial binding
is likely not applicable for Ras–effector complexes unless the
interfacial binders can trap these complexes in a state that is non-
competent for signaling. Well-devised screens should in principle
be able to identify such compounds. We expressed reservations
above against targeting the nucleotide exchange as an approach
for Ras inhibition since it would preferentially inhibit wild-type
Ras. With compounds that disrupt the effector interaction we ex-
pect to target mutant and wild-type Ras at least equally. The sites
of the Ras mutations are at the catalytic domain, distal from the
effector-binding site. It is therefore unlikely that differentiation
between mutant and wild-type Ras can be achieved using this
approach. However, cells with mutant Ras are more dependent
on signaling to effectors for their survival and proliferation than
cells with wild-type Ras. This differential dependence may
provide an adequate therapeutic window for targeting Ras-effector
interactions.
Finally, we are intrigued by the work of Kalbitzer and Herrmann
et al who identiﬁed binders that trap Ras in a conformational state
that resembles the GTP state yet has low afﬁnity to effectors.32 The
identiﬁed binders, metal cyclens (17 and 18), are not drug-like, but
the concept is compelling and deserves further investigation. Ras is
highly dynamic in its conformation, and we believe that further
studies of conformational states and modulation of Ras conforma-
tion with small molecules could open up new opportunities.
In conclusion, 30 years after the identiﬁcation of the Ras onco-
gene no effective strategies to target Ras mutant tumors are avail-
able. It is becoming increasingly evident that inhibition of effector
pathways, even with inhibitors used in combination, might not
provide a satisfactory solution. Hence, the search for direct Ras
inhibitors must continue. Targeting protein–protein interactions
with small molecules has, despite the challenges, emerged as an
accepted direction in drug discovery,60 and the Ras oncoproteins
are unlikely to be overlooked. In fact, several groups recently re-
ported small molecule Ras binders with functional effects. The
best-characterized binding data resulted from NMR fragment
screens conducted by two independent research groups at Vander-
bilt University and at Genentech. These studies provide the ﬁrst-
ever reported examples of high-resolution Ras small-molecule
co-crystal structures and reveal clear opportunities for identifying
higher afﬁnity binders. Both compound series act as inhibitors of
nucleotide exchange. For the reasons elucidated above, we are
doubtful about the beneﬁt and safety proﬁle associated with this
MOA. It remains to be seen if these binding sites can be utilized
for developing binders that can block the interaction of Ras with
its effector molecules. Ras has a variety of partner proteins, the
nucleotide exchange factors, GAPs and many effector proteins with
signiﬁcant overlap in their respective binding surfaces, and it may
be challenging to selectively address one set of interactions with-
out affecting others. For this reason it will be important to comple-
ment the biophysical studies with appropriate biochemical/
mechanistic assays that provide information on immediate mech-
anistic consequences as well as physiological consequences further
downstream.
An alternative to using fragment screens for lead discovery
could be function-based HTS screens that utilize well-deﬁned
mechanistic readouts, for example Ras association with a selected
effector. Such efforts could be particularly powerful if the setup of
the screen provides selectivity information, such as differential ef-
fects in mutant versus non-mutant Ras. While in theory compel-
ling, such strategies have been tried by us and others, they were
found to be prone to high false-positive hit rates hampering the
identiﬁcation of truly valuable starting points. Nevertheless, com-
pounds have been identiﬁed from these efforts, such as MCP110
(20), a compound proven to disrupt Ras–Raf association and elicit-
ing cellular responses consistent with this MOA. We suggest that
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ing the identiﬁcation of compounds with interesting mechanistic
proﬁles. We believe that the complexities of the system are too
high to attempt optimization in the absence of this information.
Clearly, biophysical characterization may not always be straight-
forward; for example, Brefeldin A (19), which acts as an interfacial
inhibitor of a GTPase and its nucleotide exchange factor, has no
afﬁnity to either protein and would have been missed by a frag-
ment screen identifying Arf1 binders. Elucidation of its mechanism
and unique binding characteristics required the study of the dy-
namic process of the nucleotide exchange mechanism. Speciﬁc
mutant forms of Ras that conformationally resemble known cata-
lytic transition states61,62 could prove highly valuable for biophys-
ical studies, and we think that this is an interesting direction worth
further exploration.
In essence, we believe that both biophysical screens and func-
tional screens can be starting points, but mechanistic characteriza-
tion of biophysical screening hits and biophysical characterization
of functional hits are necessary as immediate follow-up steps prior
to investigating functional effects in cells, which are more prone to
confounding off-target activities. Such efforts will be resource-
intensive and require well-integrated and experienced biophysics,
biochemistry, and medicinal chemistry teams.
Biophysical understanding:
- Binding site
- Binding affinity
Mechanistic understanding:
- Effect on partner protein association
- Selectivity
The above comments addressed mainly the druggability of Ras. An-
other important consideration, which is at least equally challenging,
is selectivity. An ideal therapeutic would selectively inhibit mutant
K-Ras while sparing other GTPases, including the close family mem-
bers H- and N-Ras, and wild-type K-Ras. It is unlikely such a proﬁle
can be achieved with a Ras-binding molecule. Mutant versus wild-
type selectivity in particular will be a major challenge since the
mutation is distal from the effector-binding site. Given the central
role of Ras in coupling extracellular receptor signals to multiple
intracellular signaling pathways governing cell growth, differentia-
tion, and other vital cellular processes, we believe that stringent
selectivity requirements are necessary in order to achieve an ade-
quate therapeutic window. However, at this point we can only spec-
ulate, and an accurate assessment of the selectivity requirements
will need to be revisited once sufﬁciently potent tool compounds
are available.
The identiﬁcation of therapeutically useful Ras binders will re-
quire well-staffed teams with strong biology, biophysical, and
medicinal chemistry expertise, and such efforts require robust
funding and long-term commitment. Given the signiﬁcant chal-
lenges and extensive failures encountered in decades of Ras re-
search, companies are not inclined to taking such risks in the
current economic and business climate. Nevertheless, the large un-
met medical need and profound therapeutic beneﬁt in developing
Ras inhibitors mandate continued efforts in this ﬁeld. Alliances be-
tween companies and academic labs offer perhaps the best way to
tackle this challenge by bridging different perspectives (exploratory
research vs therapeutic development, long term commitment vs
short term deliverables), leveraging core expertise (e.g. Ras biology,
fragment-based drug discovery) and sharing risks, andwe are hope-
ful to see such partnerships evolving in the near future.
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